Patents
The following is a list of Flex Pharma products and the U.S. patents that may apply to them. This list is presented for informational purposes and may not be all-inclusive. Additional patents may apply.
Patents listed below may have expired or been invalidated. Patents pending are not listed. The information on this page is updated periodically as new patents are issued, when new products are introduced, when patents expire, or when products are discontinued.
| Product | Active Ingredient | Indication | U.S. Patents |
|---|---|---|---|
| * CAVHANZA™ is a trademark of Flex Pharma, LLC † PHYRAGO® is a registered trademark of Handa Therapeutics, LLC ‡ Flex Pharma, LLC is no longer the owner of these patents |
|||
CAVHANZA™*www.cavhanza.com ↗ |
Nilotinib | Ph+ CML | US Patent No. 11,389,450 US Patent No. 11,559,485 US Patent No. 12,016,861 US Patent No. 12,029,740 |
PHYRAGO®†‡www.phyrago.com ↗ |
Dasatinib | Ph+ CML, PH+ ALL | US Patent No. 11,202,778 US Patent No. 11,298,356 US Patent No. 11,324,745 US Patent No. 12,433,891 US Patent No. 12,465,606 US Patent No. 12,544,376 |
The patents identified above are believed to apply to the listed Flex Pharma products at the time of publication. This patent listing is provided in compliance with the virtual marking provisions of the Leahy-Smith America Invents Act, 35 U.S.C. § 287(a). The list may not be exhaustive — additional patents may apply, and patents may issue or expire after the date this list was last updated.
For inquiries regarding Flex Pharma intellectual property or to report a possible infringement, please contact:
FLEX PHARMA, LLC
Attn: Legal Department
639 Campus Drive, New Brighton, MN 55112
legal@flexpharmausa.com